KRAS, NRAS, BRAF Genes Mutations in the Tumor Substrate from Bone Marrow, ctDNA and Plasmacytomas in Multiple Myeloma (MM)

被引：0
|
作者：
Soloveva, Maya [1 ]
Solovev, Maxim [1 ]
Nikulina, Elena [1 ]
Risinskaya, Natalya [1 ]
Biderman, Bella [1 ]
Yakutik, Igor [1 ]
Obukhova, Tatyana [1 ]
Sudarikov, Andrey [1 ]
Julhakyan, Hunan [1 ]
Mendeleeva, Larisa [1 ]
机构：
[1] Natl Med Res Ctr Hematol, Moscow, Russia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
multiple myeloma; KRAS; NRAS; BRAF; genes mutations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-249
引用
收藏
页码：S485 / S485
页数：1
相关论文
共 37 条
  • [31] Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells
    Katodritou, Eirini
    Terpos, Evangelos
    North, Janet
    Kottaridis, Panagiotis
    Verrou, Evgenia
    Gastari, Vasiliki
    Chadjiaggelidou, Christina
    Sivakumaran, Shivajanani
    Jide-Banwo, Samuel
    Tsirogianni, Maria
    Kapetanos, Dimitrios
    Zervas, Konstantinos
    Lowdell, Mark W.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (12) : 967 - 973
  • [32] DECREASE IN CLONOGENIC TUMOR-CELLS IN BONE-MARROW ASPIRATES FROM MULTIPLE-MYELOMA PATIENTS DUE TO THE INCORPORATION OF CYCLOPHOSPHAMIDE INTO TREATMENT WITH VINCRISTINE, ADRIAMYCIN AND METHYL PREDNISOLONE
    BELL, JBG
    MILLAR, BC
    MONTESBORINAGA, A
    JOFFE, JK
    CUNNINGHAM, D
    MANSI, J
    TRELEAVEN, J
    VINER, C
    MCELWAIN, TJ
    [J]. HEMATOLOGICAL ONCOLOGY, 1990, 8 (06) : 347 - 353
  • [33] Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients
    Nijhof, Inger S.
    de Weers, Michel
    Andre, Pascale
    van Kessel, Berris
    Lokhorst, Henk M.
    Parren, Paul W. H. I.
    Morel, Yannis
    Mutis, Tuna
    [J]. BLOOD, 2011, 118 (21) : 813 - 813
  • [34] Bone marrow microenvironment (ME) associated genes identified prior to all altered 48 hours after bortexomib test-dose application and prognosis of multiple myeloma (MM) treated with total therapy 3 (TT3)
    Qu, P.
    Haessler, J.
    Barlogie, B.
    Shaughnessy, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Lineage commitment of CD34+ cells from steady-state bone marrow (BM) and peripheral blood stem cells (PBSC) harvests: A comparison between healthy donors and multiple myeloma (MM) patients
    Papadhimitriou, SI
    Spanakos, G
    Baxevanis, CN
    Filis, I
    Tsaftaridis, P
    Stamatelou, M
    Papamichail, M
    [J]. EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 423 - 423
  • [36] Bone marrow (BM) and peripheral blood (PB) dendritic cells (DC's) from patients with multiple myeloma (MM) are the phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpes virus (KSHV) gene sequences.
    Raje, N
    Gong, J
    Chauhan, D
    Teoh, G
    Avigan, D
    Wu, Z
    Chen, D
    Treon, SP
    Webb, I
    Kufe, D
    Anderson, KC
    [J]. BLOOD, 1998, 92 (10) : 95A - 95A
  • [37] Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
    Sklavenitis-Pistofidis, Romanos
    Wu, Ting
    Rahmat, Mahshid
    Konishi, Yoshinobu
    Lightbody, Elizabeth D.
    Timonian, Michael
    Tsuji, Junko
    Firer, Danielle T.
    Haradhvala, Nicholas J.
    Soekojo, Cinnie Yentia
    Wang, Xiyue
    Heilpern-Mallory, Daniel
    Aguet, Francois
    Getz, Gad
    Ghobrial, Irene
    [J]. BLOOD, 2022, 140
1234